Program
zimberelimab
Also written as “Zimberelimab”, “GLS-010” and “AB122”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms · Adenocarcinoma Of Esophagus · Neoplasm Metastasis · Biliary Tract Neoplasms, led by 5 companies.
Drug pageZimberelimab: every studyMany companies study it; this page follows only the 20 they lead. All 51 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Guangzhou Gloria Biosciencesits history only | 74 open or running | phase 3since Aug 19, 2022 | Aug 28, 2018 | Dec 2026phase 2 · NCT05909436 |
| Arcus Biosciencesits history only | 60 open or running | phase 3since Oct 3, 2022 | Jul 17, 2018 | none ahead |
| Gilead Sciencesits history only | 43 open or running | phase 3since Aug 12, 2022 | Apr 26, 2018 | Jun 2028phase 3 · NCT05502237 |
| Otsukaits history only | 22 open or running | phase 3since Jul 3, 2026 | Jul 27, 2021 | Jun 2027phase 1 · NCT04999761 |
| RemeGenits history only | 11 open or running | phase 2since Nov 23, 2023 | Nov 23, 2023 | Jun 30, 2027phase 2 · NCT06155396 |
Also a collaborator on its studies: Merck KGaA, Darmstadt, Germany and Strata Oncology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Apr 26, 2018.
- Aug 29, 2019Phase 1 study in Advanced Solid TumorsArcus Biosciences · NCT04087018 · 18 enrolled · United States
- Jan 23, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungArcus Biosciences · NCT04262856 · 151 enrolled · United States, Australia, Canada and more
- Jun 9, 2020Named zimberelimabINNProposed as its International Nonproprietary Name in WHO's List 123 · before, GLS-010, AB122
- Jan 29, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungArcus Biosciences · NCT04736173 · 169 enrolled · United States, Hong Kong, Malaysia and more
- Feb 5, 2021Phase 1 study in Advanced Solid TumorsGilead Sciences · NCT04747470 · 13 enrolled · United States
- Jul 27, 2021Otsuka’s first study: phase 1 study in Neoplasm MetastasisNew to OtsukaOtsuka · NCT04999761 · 917 planned · Japan
- Aug 12, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungGilead Sciences · NCT05502237 · 1,021 enrolled · United States, Argentina, Austria and more
- Aug 19, 2022Phase 3 study in RecurrenceGuangzhou Gloria Biosciences · NCT05518318 · 60 planned
- Oct 3, 2022Phase 3 study in Adenocarcinoma Of EsophagusArcus Biosciences · NCT05568095 · 1,040 enrolled · United States, Argentina, Australia and more
- Nov 21, 2022Phase 2 study in Lung NeoplasmsGilead Sciences · NCT05633667 · 192 enrolled · United States, Brazil, Hong Kong and more
- Dec 26, 2022Phase 3 study in RecurrenceGuangzhou Gloria Biosciences · NCT05798819 · 424 planned · China
- May 4, 2023Phase 2 study in Solid TumorGuangzhou Gloria Biosciences · NCT05909436 · 107 planned · China
- Jul 26, 2023Phase 2 study in Advanced Non-Small Cell Lung CancerGuangzhou Gloria Biosciences · NCT05978401 · 152 planned · China
- Nov 23, 2023RemeGen’s first study: phase 2 study in Uterine Cervical NeoplasmsNew to RemeGenRemeGen · NCT06155396 · 116 planned · China
- Jul 3, 2026Phase 3 study in Biliary Tract NeoplasmsPhase 3 reachedOtsuka · NCT07710885 · 784 planned · Australia, Japan, South Korea and more
Ahead
- Dec 2026Primary completion: phase 2 study in Solid TumorGuangzhou Gloria Biosciences · NCT05909436
- Jun 2027Primary completion: phase 1 study in Neoplasm MetastasisOtsuka · NCT04999761
- Jun 30, 2027Primary completion: phase 2 study in Uterine Cervical NeoplasmsRemeGen · NCT06155396
- Jun 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungGilead Sciences · NCT05502237
TargetBeta
“A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07710885Biliary Tract Neoplasms · Australia, Japan, South Korea and more | 3 | Recruiting | Otsuka | Apr 30, 2030 | 784 |
| NCT06155396Uterine Cervical Neoplasms · China | 2 | Recruiting | RemeGen | Jun 30, 2027 | 116 |
| NCT05978401Advanced Non-Small Cell Lung Cancer · China | 2 | Not yet recruiting | Guangzhou Gloria Biosciences | Apr 1, 2025 | 152 |
| NCT05909436Solid Tumor · China | 2 | Recruiting | Guangzhou Gloria Biosciences | Dec 2026 | 107 |
| NCT05798819Recurrence · China | 3 | Recruiting | Guangzhou Gloria Biosciences | Dec 31, 2029 | 424 |
| NCT05633667Lung Neoplasms · United States, Brazil, Hong Kong and more | 2 | Active, not recruiting | Gilead Sciences | Sep 2029 | 192 |
| NCT05568095Adenocarcinoma Of Esophagus · United States, Argentina, Australia and more | 3 | Completed | Arcus Biosciences | Aug 28, 2026 | 1,040 |
| NCT05518318Recurrence | 3 | Not yet recruiting | Guangzhou Gloria Biosciences | Jun 2025 | 60 |
| NCT05502237Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more | 3 | Active, not recruiting | Gilead Sciences | Jun 2028 | 1,021 |
| NCT04999761Neoplasm Metastasis · Japan | 1 | Recruiting | Otsuka | Jun 2027 | 917 |
| NCT04747470Advanced Solid Tumors · United States | 1 | Terminated | Gilead Sciences | Nov 7, 2022 | 13 |
| NCT04736173Carcinoma, Non-Small-Cell Lung · United States, Hong Kong, Malaysia and more | 2 | Completed | Arcus Biosciences | Sep 17, 2026 | 169 |
| NCT04262856Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Completed | Arcus Biosciences | Jul 9, 2025 | 151 |
| NCT04087018Advanced Solid Tumors · United States | 1 | Completed | Arcus Biosciences | Jun 17, 2024 | 18 |
| NCT03972722Uterine Cervical Neoplasms · China | 2 | UNKNOWN | Guangzhou Gloria Biosciences | May 15, 2022 | 89 |
| NCT03846310Carcinoma, Non-Small-Cell Lung · United States, Korea, Republic of, Singapore and more | 1 | Completed | Arcus Biosciences | Nov 18, 2024 | 77 |
| NCT03713905Advanced Solid Tumors · China | 1 | Completed | Guangzhou Gloria Biosciences | Feb 28, 2022 | 293 |
| NCT03655483Classical Hodgkin's Lymphoma · China | 2 | UNKNOWN | Guangzhou Gloria Biosciences | Apr 11, 2021 | 85 |
| NCT03629756Carcinoma, Non-Small-Cell Lung · United States, Australia | 1 | Completed | Arcus Biosciences | Aug 18, 2021 | 48 |
| NCT03547973Metastatic Urothelial Cancer · United States, France, Germany and more | 2 | Active, not recruiting | Gilead Sciences | Apr 2030 | 502 |
How it is read
Names in the registry
- “Zimberelimab”, 10 entries
- “GLS-010”, 6 entries
- “AB122”, 2 entries
- “GLS-012+GLS-010”, 2 entries
- “Zimberelimab (ZIM)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Uterine Cervical Neoplasms, 2 studies
- Adenocarcinoma Of Esophagus, 1 study
- Neoplasm Metastasis, 1 study
- Biliary Tract Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.